Category: P04 - Newborn affected by noxious substances transmitted via placenta or breast milk

 Chapter Notes

 Section Notes

 P04

Newborn affected by noxious substances transmitted via placenta or breast milk

nonteratogenic effects of substances transmitted via placenta

Code first any current condition in newborn, if applicable

congenital malformations (Q00-Q99)

encounter for observation of newborn for suspected diseases and conditions ruled out (Z05.-)

neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother (P58.4)

newborn in contact with and (suspected) exposures hazardous to health not transmitted via placenta or breast milk (Z77.-)

 P04.0

Newborn affected by maternal anesthesia and analgesia in pregnancy, labor and delivery

Newborn affected by reactions and intoxications from maternal opiates and tranquilizers administered for procedures during pregnancy or labor and delivery

newborn affected by other maternal medication (P04.1-)

 P04.1

Newborn affected by other maternal medication

Code first, if applicable, withdrawal symptoms from maternal use of drugs of addiction (P96.1)

withdrawal symptoms from therapeutic use of drugs in newborn (P96.2)

dysmorphism due to warfarin (Q86.2)

fetal hydantoin syndrome (Q86.1)

maternal anesthesia and analgesia in pregnancy, labor and delivery (P04.0)

maternal use of drugs of addiction (P04.4-)

 P04.11

Newborn affected by maternal antineoplastic chemotherapy

 P04.12

Newborn affected by maternal cytotoxic drugs

 P04.13

Newborn affected by maternal use of anticonvulsants

 P04.14

Newborn affected by maternal use of opiates

 P04.15

Newborn affected by maternal use of antidepressants

 P04.16

Newborn affected by maternal use of amphetamines

 P04.17

Newborn affected by maternal use of sedative-hypnotics

 P04.1A

Newborn affected by maternal use of anxiolytics

 P04.18

Newborn affected by other maternal medication

 P04.19

Newborn affected by maternal use of unspecified medication

 P04.2

Newborn affected by maternal use of tobacco

Newborn affected by exposure in utero to tobacco smoke

newborn exposure to environmental tobacco smoke (P96.81)

 P04.3

Newborn affected by maternal use of alcohol

fetal alcohol syndrome (Q86.0)

 P04.4

Newborn affected by maternal use of drugs of addiction

 P04.40

Newborn affected by maternal use of unspecified drugs of addiction

 P04.41

Newborn affected by maternal use of cocaine

 P04.42

Newborn affected by maternal use of hallucinogens

newborn affected by other maternal medication (P04.1-)

 P04.49

Newborn affected by maternal use of other drugs of addiction

newborn affected by maternal anesthesia and analgesia (P04.0)

withdrawal symptoms from maternal use of drugs of addiction (P96.1)

 P04.5

Newborn affected by maternal use of nutritional chemical substances

 P04.6

Newborn affected by maternal exposure to environmental chemical substances

 P04.8

Newborn affected by other maternal noxious substances

 P04.81

Newborn affected by maternal use of cannabis

 P04.89

Newborn affected by other maternal noxious substances

 P04.9

Newborn affected by maternal noxious substance, unspecified